Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18631249 | 0.78 | ACSS2 (0.42) | BACE1TLR8NUDT1ADORA2A | |
| SCHEMBL18650877 | 0.76 | F10 (0.39) | BACE1TLR8NUDT1ADORA2A | |
| SCHEMBL18630764 | 0.72 | HRH3 (0.39) | BACE1TLR8NUDT1ADORA2A | |
| SCHEMBL8336656 | 0.72 | LMNA (0.44) | LMNAPKMNPSR1KDM4EAPOBEC3A | |
| SCHEMBL25679737 | 0.69 | KDM4E (0.57) | KDM4E | |
| SCHEMBL19436566 | 0.69 | JAK2 (0.62) | BACE1TLR8NUDT1CXCR4 | |
| SCHEMBL19436506 | 0.69 | JAK2 (0.62) | BACE1TLR8NUDT1CXCR4 | |
| SCHEMBL24463198 | 0.68 | CLK4 (0.41) | BACE1TLR8NUDT1LMNAPKM | |
| SCHEMBL24175386 | 0.68 | JAK2 (0.48) | BACE1TLR8NUDT1ADORA2A | |
| SCHEMBL1468359 | 0.67 | ADORA2A (0.66) | TLR8ADORA2ALMNAKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350170-B1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2022-01-26 | — | — | EP | disclosed |
| CN-108290879-B | Heteroaryl compounds as IRAK inhibitors and uses thereof | 默克专利有限公司 | 2022-01-11 | — | — | CN | disclosed |
| CN-108602776-B | Heteroaryl compounds as IRAK inhibitors and uses thereof | 默克专利有限公司 | 2021-12-03 | — | — | CN | disclosed |
| EP-3350177-B1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-07-07 | — | — | EP | disclosed |
| US-10392375-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-08-27 | — | — | US | disclosed |
| US-10059701-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2018-08-28 | — | — | US | disclosed |
| US-20180237426-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-08-23 | — | — | US | disclosed |
| US-20180237413-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-08-23 | — | — | US | disclosed |
| EP-3350177-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2018-07-25 | — | — | EP | disclosed |
| EP-3350170-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2018-07-25 | — | — | EP | disclosed |
| US-9969710-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2018-05-15 | — | — | US | disclosed |
| WO-2017049069-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017049068-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | WO | disclosed |
| US-20170081307-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237426-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | BACE1 1434/4885TLR8 40/4885NUDT1 2474/4885 |
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | BACE1 1434/4885TLR8 40/4885NUDT1 2474/4885 |
| US-20180237413-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | BACE1 1434/4885TLR8 40/4885NUDT1 2474/4885 |
| US-10392375-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | IRAK2, IRAK3, IRAK1 | BACE1 1434/4885TLR8 40/4885NUDT1 2474/4885 |
| US-10059701-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | IRAK2, IRAK3, IRAK1 | BACE1 1434/4885TLR8 40/4885NUDT1 2474/4885 |
| US-20170081307-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | BACE1 1434/4885TLR8 40/4885NUDT1 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.